American Glove Act of 2026

The American Glove Act of 2026 (HR10650) was introduced in the House on October 1, 2026, by Rep. Mike Carey (R-OH) and referred to the Committee on Oversight and Government Reform. The bill is in its earliest legislative stage with no cosponsors and no committee action beyond referral. Its stated purpose is to ensure that federal procurement of nitrile gloves complies with the Make PPE in America Act, which already establishes a preference for domestically manufactured personal protective equipment.

The bill does not authorize or appropriate any funding. Instead, it defines 'covered nitrile gloves' and 'qualified domestic manufacturer' with strict criteria—requiring US-based manufacturing, majority US ownership, no foreign entity of concern control, and demonstrated commercial-scale capacity. It then mandates that covered agencies (DHS, HHS, VA, DoD, and others) procure such gloves only from qualified domestic manufacturers through any shared procurement vehicle. This is a procurement mandate, not a spending bill.

The money trail is indirect: the bill would redirect existing government glove spending toward US manufacturers. The federal government is a significant buyer of medical exam gloves, but the total addressable market for nitrile gloves is dominated by foreign producers (Malaysia, Thailand). A domestic preference could shift a portion of that spending to US firms. However, without appropriations, the bill itself creates no new contract dollars.

Structural winners are US-based nitrile glove manufacturers. The most prominent publicly traded US company with a clear nitrile exam glove product line is Kimberly-Clark through its Professional segment. Other potential beneficiaries include Honeywell ($HON) and 3M ($MMM), which have industrial and medical glove lines, but their exposure to government medical glove procurement is smaller. The bill's narrow scope—only nitrile gloves, only federal procurement—limits its market-wide impact.

The legislative timeline is uncertain. The bill must pass the House Oversight Committee, then the full House, then the Senate, and be signed by the President. Given the current session (119th Congress, 2025-2027) and the bill's introduction late in the second session, passage is unlikely without significant bipartisan momentum. The bill's sponsor is a junior member, and there are no cosponsors, indicating low initial support.